(Q24236673)

4

0 references

Goran Poropat

object named as

Goran Poropat

1

0 references

Davor Stimac

object named as

Davor Stimac

3

0 references

author name string

Vanja Giljaca

Cochrane Database of Systematic Reviews

2

0 references

publication date

17 March 2010

0 references

published in

0 references

cites work

A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

A prospective, randomized, double-blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Patterns of graft rejection following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Bile acids for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Bile acids for viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Cyclosporin versus tacrolimus for liver transplanted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Adult liver transplantation: what non-specialists need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Imaging of hepatic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Unique aspects of rejection and tolerance in liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

The effect of drugs on bile flow and composition. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Bile-acid-induced cell injury and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Overcoming the limitations of current meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Liver transplantation: making the best out of what we have.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Immunologic mechanisms of hepatic allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen or Peyer's patches in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Bile acids for liver-transplanted patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Rejection in liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Characteristics of biliary lipid metabolism after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Hepatoprotective properties of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Intrahepatic cholestasis after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

A possible role of ursodeoxycholic acid in liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005442.PUB2

7 January 2021

10.1002/14651858.CD005442.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4333595

OpenCitations bibliographic resource ID

4333595

1 reference